Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555161 · ClinicalTrials.gov registry record · NA
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
A NA study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Aria CV.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 12
- Study locations
NCT04555161: Recruiting NA study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Aria CV.
NCT04555161 is a NA study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that is actively recruiting participants, run by Aria CV. The registered enrollment target is 30 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04555161, a NA study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Aria CV.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Primary Outcome
The primary safety endpoint is the incidence of investigational device- or procedure-related serious adverse events through 30 days post-index procedure.
Conditions Studied
Interventions
- DEVICE Aria CV Pulmonary Hypertension System
Study Locations (12)
California
- University of California - San Diego - La Jolla
- University of California-Los Angeles - Los Angeles
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
New York
- Cornell University - New York
- University of Rochester - New York
Ohio
- The Christ Hospital - Cincinnati
- Ohio Health - Columbus
Indiana
- St. Vincent Health - Indianapolis
Massachusetts
- Brigham and Women's Hospital - Boston
South Carolina
- Medical University of South Carolina - Charleston
Wisconsin
- Aurora St Luke's Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT04555161 shows while recruiting
NCT04555161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Aria CV Pulmonary Hypertension System is the first listed.
NCT04555161 lists 12 locations in 8 states (California, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT04555161 about?
NCT04555161 is a clinical study titled "Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System". This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
What is the current status of trial NCT04555161?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-03-15. Estimated completion is 2026-10.
What conditions does trial NCT04555161 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Heart Dysfunction.
What interventions are being tested in trial NCT04555161?
The interventions under investigation include: Aria CV Pulmonary Hypertension System (DEVICE).
Who is sponsoring clinical trial NCT04555161?
This trial is sponsored by Aria CV, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04555161 being conducted?
This trial has 12 study locations across California, Indiana, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04555161's enrollment target sits among peer trials
30 49th of 72 higher than 24 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Identifying Right Ventricular Dysfunction in COPD Through Right Heart Catheterization, Imaging and Exercise
RECRUITING · NA
-
iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH
RECRUITING · NA
-
Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia
RECRUITING · NA
-
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI